A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression
Overall Survival (OS) [Time Frame: Up to approximately 36 months] Progression free survival (PFS) [Time Frame: Up to approximately 36 months]
Why this Research Matters
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Who can Participate
Age 18 years old at the time of enrollment Eastern Cooperative Oncology Group (ECOG) performance status score of 0 - 1 Expected life expectancy 3 months Metastatic (Stage IV) NSCLC Histologically or cytologically confirmed squamous or non-squamous NSCLC Tumor demonstrates high PD-L1 expression ( TPS>50%) based on a 22C3 immunohistochemistry ( IHC) clinical assay approved / cleared by local health authorities. At least one measurable noncerebral lesion according to RECIST 1.1 No prior systemic treatment for metastatic NSCLC.
Study ID
Protocol Number: 25-0500
More information available at ClinicalTrials.gov: NCT06767514
Meet the Team
Principal Investigator